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that these commonly used anesthetics increase risk in hemody-
namically stable patients, their use is recommended.
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Biomarker Sensitivity
and Specificity Require
Pre-Test Probability of
Disease Diagnosis to Be Collated
Additional Points on the
Interpretation of Pro–B-Type
Natriuretic Peptide Triage of
Dyspnea in the Copenhagen Heart Study
The Copenhagen City Heart study (1) provides important insight
into community assessment of breathlessness. The report could be
taken to support pro–B-type natriuretic peptide (proBNP) triage
of all breathless patients in this setting. We feel this is a simplistic
analysis of the potential contribution of biomarker technology and
that a number of additional points should be considered.
The relationship of BNP measures to cardiac impairment has
been confirmed, and their utility tested in a variety of settings (1,2).
However, the sampling frame of most surveys (2,3) is of little
relevance to the general practitioner. Importantly in the Copen-
hagen study, 48% of their breathless patients had neither cardiac
nor pulmonary abnormality. In fact, the major causes of dyspnea in
a population-based study were obesity, depression, and older age
(4). Thus, even before addressing the performance of proBNP
analysis, the authors must surely also address the relative diagnostic
void that is presented for almost half of the patients in their study.
Secondly, the incremental value of proBNP testing is not clearly
put in the context of clinical history; physical examination and
simple bedside tests such as a 12-lead electrocardiogram and a
chest roentgenogram. Although these may individually have low
sensitivity and specificity and are operator specific (5,6), they
contribute to pre-test diagnostic probability, which, in turn, affects
the performance of any biomarker and the post-test probability of
the presence of cardiac dysfunction (7). By excluding the contri-
bution of the physician, the ability of the test to function
cost-effectively could alternatively be compromised or enhanced.
Thus, a dyspneic patient with a high proBNP level could undergo
echocardiography, even in the absence of abnormalities on exam-
ination and bedside investigations. Surely in such patients re-
sources would be better employed establishing a noncardiac cause
for dyspnea.
Thirdly, although the authors accounted for age and gender,
they need to interpret point measurement of proBNP levels with
great care due to their large intraindividual and interindividual
variability (33.3% and 36.5%, respectively, in normal individuals
[8]). Both symptomatic and asymptomatic patients with stable
systolic heart failure present with wide ranges of plasma BNP, with
up to 21% of symptomatic patients having BNP levels below what
would be considered “diagnostic”(9).
Finally, the concept that pulmonary disease can be defined by
spirometry alone is not acceptable. This limited technique does not
rule out the presence of significant parenchymal lung disease.
Moreover, proBNP levels can be elevated in lung conditions
resulting in right heart strain and pulmonary hypertension (10,11).
The authors are to be congratulated on their effort in challeng-
ing the use of biomarker technology for the community assessment
of breathlessness. However, its commercial exploitation needs to
be based on its cost-effectiveness and applicability to realistic
clinical practice. It needs to be interpolated in the light of clinical
assessment, particularly given the large percentage of true negative
results for either cardiac or pulmonary abnormalities.
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Reply
We would like to thank Drs. MacFadyen and Chuen for their interest
in our study (1). They seem to conclude that our population-based
report advocates screening for all persons with dyspnea. Unfortu-
nately, the majority of the issues they raise are based on this false
assumption. We believe that it is necessary to await the results from
studies evaluating the cost-effectiveness before introducing pro–B-
type natriuretic peptide (proBNP) as a screening tool of all breathless
persons in the community. We agree that if one sought to examine
the cost-effectiveness of the natriuretic peptides in primary care, they
should include the additional information that is obtainable for the
general practitioner.
The aim of our study was to examine whether or not plasma
proBNP could be used in discriminating between cardiac and pulmo-
nary dysfunction in the general population with dyspnea. Our findings
that plasma proBNP is increased in left ventricular dilation, hyper-
trophy, systolic and diastolic dysfunction, but unaffected by pulmonary
dysfunction, should be viewed in this perspective. Drs. MacFadyen
and Chuen also point out that 48% of the population in our study
reported dyspnea without having an abnormal conventional echocar-
diogram or pulmonary function test. It is important to emphasize that
a normal conventional echocardiogram does not rule out cardiac
dysfunction. Most of these people (83%) were only complaining of
mild dyspnea. Compared with their nondyspneic counterparts, they
had a higher frequency of ischemic heart disease and risk factors for
ischemic heart disease. Conventional echocardiography does not
provide much information about longitudinal myocardial contractility,
which is impaired initially in ischemic heart disease. In fact, we
suspect that breathless persons with a high level of plasma proBNP
have a high risk of cardiac dysfunction, although they might have
normal conventional echocardiograms. Further research with more
advanced modalities (e.g., tissue Doppler imaging) within such groups
is needed.
Intraindividual and interindividual variability of plasma
proBNP should not be extrapolated from studies of BNP or
N-terminal proBNP. The interindividual variability is one of the
major reasons for the assay’s gray zone reported in our study,
whereas the intraindividual variability of the assay is small (2).
Regarding the ability to rule out parenchymal lung disease by
spirometry, pulse oxymetry, and clinical history, we agree that
additional information from computed tomography scans and lung
biopsy would have been interesting but obviously not possible in
this population study. Concerning the last issue of pulmonary
hypertension in parenchymal lung disease, we have previously
shown that plasma proBNP only increases at elevated mean
pulmonary artery pressures 50 mm Hg in patients with terminal
parenchymal lung disease (3).
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Plaque Burden,
Intravascular Ultrasound, and
Distal Embolization Phenomenon
Although embolization of atherothrombotic material during stent
deployment is probably ubiquitous, its causes and consequences
remain poorly characterized. In a recent issue of the Journal, both
Kawaguchi et al. (1) and Kawamoto et al. (2) suggested that vessels
most likely to sustain distal embolization could be identified using
virtual histology (VH) intravascular ultrasound (IVUS) to quantify
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